Xencor (NASDAQ:XNCR) Stock Rating Lowered by StockNews.com

Xencor (NASDAQ:XNCR) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Friday.

XNCR has been the topic of several other research reports. Piper Sandler raised shares of Xencor from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $20.00 to $30.00 in a research note on Monday, December 2nd. Wells Fargo & Company reduced their price objective on shares of Xencor from $37.00 to $33.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. One research analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $34.38.

Xencor Trading Down 2.0 %

Shares of XNCR opened at $12.87 on Friday. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01. The firm’s 50-day moving average is $17.59 and its two-hundred day moving average is $20.45. Xencor has a twelve month low of $12.80 and a twelve month high of $27.24. The firm has a market capitalization of $906.85 million, a P/E ratio of -4.02 and a beta of 0.74.

Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.81) by $0.19. The business had revenue of $52.79 million for the quarter, compared to analyst estimates of $17.14 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. On average, research analysts predict that Xencor will post -3.68 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Xencor

Large investors have recently bought and sold shares of the stock. Sterling Capital Management LLC raised its stake in shares of Xencor by 732.4% in the 4th quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 1,040 shares during the period. GF Fund Management CO. LTD. purchased a new position in shares of Xencor in the 4th quarter valued at $34,000. GAMMA Investing LLC raised its stake in shares of Xencor by 31.0% in the 4th quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 508 shares during the period. KBC Group NV raised its stake in shares of Xencor by 63.5% in the 3rd quarter. KBC Group NV now owns 3,123 shares of the biopharmaceutical company’s stock valued at $63,000 after acquiring an additional 1,213 shares during the period. Finally, Quarry LP grew its holdings in Xencor by 111.4% during the 3rd quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company’s stock valued at $80,000 after purchasing an additional 2,108 shares in the last quarter.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.